FDA Risk Communication Strategy May Include Overhaul Of Labeling Language
As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling
You may also be interested in...
How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies. But how might the decision affect FDA, and by extension, the drug review process
An FDA study to monitor prescribing decisions among care physicians who treat pregnant women could help pave the way for a better understanding of how to communicate drug risks in general
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts